Singapore Medical Device Registration: Four Evaluation Routes and Official Fees

1. Key takeaways

Singapore registers Class B, C and D medical devices through four evaluation routes: Immediate, Expedited, Abridged and Full evaluation. The core variable that decides which route a product can take is whether the product already holds approval from an HSA-recognised Reference Agency, and the number, market history and safety record of those approvals. On top of the route-specific evaluation fee, every application must also pay a uniform application fee of SGD 560. Choosing the wrong route carries a serious worst-case consequence: a registration already granted can be forfeited.

• Route eligibility is evidence-driven: it rests on the strength of overseas Reference Agency approvals, not on applicant preference, so the route analysis must be completed before submission.
• The application fee of SGD 560 applies uniformly to Class B, C and D submissions regardless of the route selected.
• Official evaluation timelines are working-day clocks that stop while HSA waits for the applicant to answer queries, so real project schedules must add preparation and response time.
• Route fees differ sharply across classes: the same Full route costs SGD 3,900 for Class B but SGD 12,000 for Class D, so budgeting must be done route by route.
• Devices in Class D that contain registrable drugs sit in a separate fee band, with the Full route at SGD 75,600, a figure that should influence product definition decisions early in development.
• Priority Review is not a fifth route; it is an acceleration option attached only to the Full route.

2. Legal basis

The rules governing registration routes in Singapore are set out in the table below. The key content is concentrated in sections 4 to 6 of GN-15, which define the four routes and the Reference Agency rules that unlock the faster pathways. Fees and timelines are taken from the official HSA fees and processing times page, and the statutory foundation is the registration provisions of the Health Products Act 2007.

The following official figures combine the uniform application fee with the route-specific evaluation fees and processing times. The uniform application fee is SGD 560 and applies to Class B, C and D alike.

3. Expert insights

Insight one: the evaluation working days and the elapsed calendar time are two different numbers and must be calculated separately.

The figures in the table above are the evaluation clocks published by HSA, and these clocks are stopped (stop-clock) while HSA is waiting for the applicant to respond to queries. In project scheduling we additionally allow for the dossier preparation period, the round trips of query responses, and the time needed to supply supplementary documents. For the Class D Full route, the 310 working days are only the evaluation segment, not the time to market.

Insight two: a route is not something you simply choose; it is something you qualify for.

Immediate, Expedited and Abridged all presuppose Reference Agency approvals (see Article 12 for detail). HSA is explicit about the consequence of getting eligibility wrong: if the applicant misjudges route eligibility, the registration already granted may be forfeited. This is precisely why we strongly recommend preparing a written route-eligibility justification before submission.

Insight three: the Class B Immediate route is the most cost-effective channel in the Singapore system.

SGD 1,000 and immediate registration upon submission make this channel extremely valuable for Class B products that already hold mature overseas approvals. Its threshold, however, requires precise counting: either one independent approval plus three years of market history, or two independent approvals. See Article 13 for the detailed reckoning.

Insight four: the cost discontinuity for drug-device combinations should be identified early.

For Class D devices containing registrable drugs, the Full route costs SGD 75,600, which is 6.3 times the ordinary Class D Full fee of SGD 12,000. Companies should know this number at the development stage, because it is large enough to influence product definition and the overall regulatory strategy.

Insight five: Priority Review is not a fifth route but an acceleration option of the Full route.

It applies only to Class B, C and D applications taking the Full route, and it cannot substitute for the eligibility assessment of the Abridged, Expedited or Immediate routes. See Article 16 for detail.

4. Practical recommendations

• Build an eligibility-cost-time matrix first: list for every SKU the routes it can take, the corresponding fees and timelines, and then rank the products by commercial priority for launch.
• Prepare a written route-eligibility justification: before submission, produce a one-page eligibility argument that cites the clauses of GN-15 sections 4–6 together with the evidence of Reference Agency approvals, and file it in the project record.
• Put query response deadlines into contracts: agree response timeframes with the registrant so that the stop-clock period does not run out of control.
• Budget fees by route tier: do not budget on an average fee, because the difference between routes can exceed a factor of five.

5. Verification checklist

• □ The risk class (A/B/C/D) of each product has been confirmed
• □ Whether Reference Agency approvals are held, and how many, has been checked
• □ A written route-eligibility justification has been completed
• □ A fee budget has been prepared by route tier, including the SGD 560 application fee
• □ Time for query responses and supplementary submissions has been included in the schedule
• □ Drug-device combination products have been costed separately

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com